A practical reference on MC4R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-20. Anything still debated is marked as such rather than presented as settled.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Alzheimer's disease (AD) can be definitively diagnosed only with histopathological findings; in the absence of autopsy or brain biopsy, clinical diagnoses of AD are "possible" or "probable", based on other findings. Up to 23% of those clinically diagnosed with AD may be misdiagnosed and may have pathology suggestive of another condition with symptoms that mimic those of AD.
== History == SPAR began in 1994 at the New England Deaconess Hospital (now Beth Israel Deaconess Medical Center) as a support group for couples wishing to parent when one of them had an incurable sexually transmitted disease. The patient couples began raising money to fund the research needed to develop the methods to improve the safety of attempting pregnancy. By 1996 sufficient funds were available to begin, but a merger between the Beth Israel Hospital and the New England Deaconess Hospital (now Beth Israel Deaconess Medical Center) necessitated the creation of an independent Massachusetts public charity, the Assisted Reproduction Foundation (now the Bedford Stem Cell Research Foundation directed by Dr. Ann Kiessling), to continue the work. Within two years, the methods for reducing, and perhaps eliminating, the risks of infection to the mother and the child were developed and Baby Ryan was born in 1999. The goal of SPAR was to provide semen testing by experts that would ensure improved safety of sperm that could then be shipped to infertility clinics near the couple's home. In this way, couples could be cared for in the same manner as other couples in their community. Fortunately, a few clinics were willing to help with this effort, and by 2002, seven collaborating clinics around the country were caring for couples living with HIV disease. In the Spring of 2000 a ground breaking study was completed, giving significant insight to the role of semen producing organs in HIV anti-viral therapy.
Further adjustments variations on BARAC to produce DIBAC/ADIBO were performed to add distal ring strain and reduce sterics around the alkyne to further increase reactivity. Keto-DIBO, in which the hydroxyl group has been converted to a ketone, has a three-fold increase in rate due to a change in ring conformation. Attempts to make a difluorobenzocyclooctyne (DIFBO) were unsuccessful due to the instability. Problems with DIFO with in vivo mouse studies illustrate the difficulty of producing bioorthogonal reactions. Although DIFO was extremely reactive in the labeling of cells, it performed poorly in mouse studies due to binding with serum albumin. Hydrophobicity of the cyclooctyne promotes sequestration by membranes and serum proteins, reducing bioavailable concentrations. In response, DIMAC (dimethoxyazacyclooctyne) was developed to increase water solubility, polarity, and pharmacokinetics, although efforts in bioorthogonal labeling of mouse models is still in development.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}M_{\mathrm {n} }&={\frac {\sum M_{i}N_{i}}{\sum N_{i}}}&&M_{\mathrm {w} }={\frac {\sum M_{i}^{2}N_{i}}{\sum M_{i}N_{i}}}\\M_{\mathrm {z} }&={\frac {\sum M_{i}^{3}N_{i}}{\sum M_{i}^{2}N_{i}}}&&M_{\mathrm {v} }=\left[{\frac {\sum M_{i}^{1+a}N_{i}}{\sum M_{i}N_{i}}}\right]^{\frac {1}{a}}\end{aligned}}}
Carbohydrate Any compound containing carbon, hydrogen, sometimes oxygen. There is considerable variety in these compounds and only some of them are available to humans as a fuel source. Cellulose, for instance, is a carbohydrate, but humans and all non-cud chewing animals (except termites and some microorganisms) can make no use of it. Only a few of the simple sugars (mono-saccharides) and even fewer of the di-saccharides (e.g., lactose) in food are available to humans. Others, if they contribute to human nutrition, do so after processing by intestinal bacteria (some estimates are that, in humans, less than 10% of caloric benefit comes from fermentation in the large intestine, as contrasted to other primates in which the proportion is rather larger). Most carbohydrates that can be absorbed and used for fuel by humans (e.g., starch and glycogen—both chains of glucose molecules).are eventually broken down to glucose during digestion. They eventually are part of the primary metabolic control mechanism. Fructose, on the other hand, is a carbohydrate which is neither; it is absorbed, but in humans processed only in the liver and in sperm, the only tissues which have the required enzymes. Ingested carbohydrate calories in non glucose forms are, in a special sense, invisible to the body.
ASBMB hosts and sponsors numerous meetings each year. The annual meeting is held each April in conjunction with the Experimental Biology meeting. Additionally, themed special symposia are organized throughout the year. The society also produces webinars throughout the year focused on topics related to scientific research, professional development and education. The society offers twenty-five different awards, grants, and scholarships.
Sources: en.wikipedia.org
In total, 32 radioisotopes have been characterised, which range in mass number from 207 to 238. After 232Th, the most stable of them (with respective half-lives) are 230Th (75,400 years), 229Th (7,916 years), 228Th (1.91 years), 234Th (24.11 days), and 227Th (18.693 days). All of these isotopes occur in nature as trace radioisotopes due to their presence in the decay chains of 232Th, 235U, 238U, and 237Np: the last of these is long extinct in nature due to its short half-life (2.14 million years), but is continually produced in minute traces from neutron capture in uranium ores. 233Th (half-life 22 minutes) occurs naturally as the result of neutron activation of natural 232Th. In deep seawaters the isotope 230Th constitutes up to 0.02% of total thorium. This is because its parent uranium is generally soluble in the ocean, but 232Th is nearly insoluble and is precipitated; thus the isotopes continually produced from uranium is relatively enriched. For this reason International Union of Pure and Applied Chemistry (IUPAC) reclassified thorium as a binuclidic element in 2013; it had formerly been considered a mononuclidic element. Thorium has a nuclear isomer, 229mTh, having the lowest known excitation energy of any isomer, measured to be 7.6±0.5 eV. This is so low that when it undergoes isomeric transition, the emitted gamma radiation is in the ultraviolet range. The nuclear transition from 229Th to 229mTh is being investigated for a nuclear clock.
=== Economics === In the United States, the price of for a vial of Humalog increased from US$35 in 2001 to $234 in 2015, or $10.06 and $29.36 per 100 units. In April 2019, Eli Lilly and Company announced they would produce a version selling for $137.35 per vial. The chief executive said that this was a contribution "to fix the problem of high out-of-pocket costs for Americans living with chronic conditions", but Patients for Affordable Drugs Now said it was just a public relations move, as "other countries pay $20 for a vial of insulin." In March 2023, Lilly announced a program capping their insulin prices at $35 per month.
The Houthis have been accused of detaining, torturing, arresting, and holding incommunicado Baháʼí Faith members on charges of espionage and apostasy, which are punishable by death. Houthi leader Abdel-Malek al-Houthi has targeted Baháʼís in public speeches, and accused the followers of Baháʼí Faith of being "satanic" and agents for the western countries, citing a 2013 fatwa issued by Iran's supreme leader.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.